PL1765337T3 - Połączenie tenofowiru, ritonawiru i TMC114 - Google Patents

Połączenie tenofowiru, ritonawiru i TMC114

Info

Publication number
PL1765337T3
PL1765337T3 PL05774136T PL05774136T PL1765337T3 PL 1765337 T3 PL1765337 T3 PL 1765337T3 PL 05774136 T PL05774136 T PL 05774136T PL 05774136 T PL05774136 T PL 05774136T PL 1765337 T3 PL1765337 T3 PL 1765337T3
Authority
PL
Poland
Prior art keywords
tenofovir
ritonavir
combination
tmc114
hiv
Prior art date
Application number
PL05774136T
Other languages
English (en)
Inventor
Richard Marinus Wilhelmus Hoetelmans
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of PL1765337T3 publication Critical patent/PL1765337T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05774136T 2004-07-08 2005-07-08 Połączenie tenofowiru, ritonawiru i TMC114 PL1765337T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103256 2004-07-08
PCT/EP2005/053266 WO2006005720A1 (en) 2004-07-08 2005-07-08 Combination of anti-hiv reverse transcriptase and protease inhibitors
EP05774136A EP1765337B1 (en) 2004-07-08 2005-07-08 Combination of tenofovir, ritonavir and tmc114

Publications (1)

Publication Number Publication Date
PL1765337T3 true PL1765337T3 (pl) 2009-02-27

Family

ID=34929311

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05774136T PL1765337T3 (pl) 2004-07-08 2005-07-08 Połączenie tenofowiru, ritonawiru i TMC114

Country Status (19)

Country Link
US (1) US20070208009A1 (pl)
EP (1) EP1765337B1 (pl)
JP (1) JP2008505870A (pl)
CN (1) CN1984654A (pl)
AT (1) ATE406161T1 (pl)
AU (1) AU2005261701A1 (pl)
BR (1) BRPI0513051A (pl)
CA (1) CA2572551A1 (pl)
DE (1) DE602005009366D1 (pl)
DK (1) DK1765337T3 (pl)
ES (1) ES2313394T3 (pl)
HR (1) HRP20080612T3 (pl)
MX (1) MXPA06014930A (pl)
NZ (1) NZ551841A (pl)
PL (1) PL1765337T3 (pl)
RU (1) RU2368380C2 (pl)
SI (1) SI1765337T1 (pl)
WO (1) WO2006005720A1 (pl)
ZA (1) ZA200700176B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055455A1 (en) * 2004-11-16 2006-05-26 Boehringer Ingelheim International, Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
AP3010A (en) * 2007-10-29 2014-10-31 Cipla Ltd Novel antiretroviral combination
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
CN102876714A (zh) * 2011-09-07 2013-01-16 深圳市易瑞生物技术有限公司 用慢病毒检测hiv耐药表型
WO2013057469A1 (en) * 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
BR112015006558A2 (pt) * 2012-10-23 2017-07-04 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus
IN2013MU01749A (pl) * 2013-05-15 2015-06-26 Cipla Ltd
EP3038607A2 (en) * 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) * 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
US10213507B2 (en) * 2017-03-10 2019-02-26 The Florida International University Board Of Trustees Compositions and methods for treating HIV-associated neurocognitive disorders
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors

Also Published As

Publication number Publication date
JP2008505870A (ja) 2008-02-28
RU2007104774A (ru) 2008-08-20
DE602005009366D1 (de) 2008-10-09
MXPA06014930A (es) 2007-02-28
ZA200700176B (en) 2008-04-30
BRPI0513051A (pt) 2008-04-22
ATE406161T1 (de) 2008-09-15
EP1765337A1 (en) 2007-03-28
AU2005261701A1 (en) 2006-01-19
RU2368380C2 (ru) 2009-09-27
NZ551841A (en) 2009-04-30
EP1765337B1 (en) 2008-08-27
ES2313394T3 (es) 2009-03-01
CA2572551A1 (en) 2006-01-19
DK1765337T3 (da) 2009-01-05
WO2006005720A1 (en) 2006-01-19
SI1765337T1 (sl) 2009-02-28
CN1984654A (zh) 2007-06-20
US20070208009A1 (en) 2007-09-06
HRP20080612T3 (en) 2009-01-31

Similar Documents

Publication Publication Date Title
HRP20080612T3 (en) Combination of tenofovir, ritonavir and tmc114
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
MXPA05002814A (es) Formulacion para agentes lipofilicos.
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
NO20045323L (no) Antistoffer
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
PT1318791E (pt) Composicao farmaceutica semi-solida de isotretinoina
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
PT971717E (pt) Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
AP2001002369A0 (en) Pharmaceutical complex.
NO983437D0 (no) Administreringsformer med umiddelbar frigivelse, samt fremgangsmÕte for fremstilling av slike
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE